KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

키워드

참고문헌 (414)

1. European Association for the Study of the Liver (EASL), "EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease", Obes Facts, 9, pp.65~90 (2016)
2. The Lancet Gastroenterology Hepatology, "Redefining non-alcoholic fatty liver disease : what’s in a name?", Lancet Gastroenterol Hepatol, 5, pp.419~ (2020)
3. Eslam M, "MAFLD : a consensus-driven proposed nomenclature for metabolic associated fatty liver disease", Gastroenterology, 158, pp.1999~2014.e1 (2020)
4. Chang Y, "Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease", Clin Chem, 53, pp.686~692 (2007)
5. Chang Y, "Metabolically healthy obesity and the development of nonalcoholic fatty liver disease", Am J Gastroenterol, 111, pp.1133~1140 (2016)
6. Min Jung Lee, "Age-Related Decrease in Skeletal Muscle Mass Is an Independent Risk Factor for Incident Nonalcoholic Fatty Liver Disease: A 10-Year Retrospective Cohort Study", Gut and Liver, 13(1), pp.67~76 (2019), 거트앤리버 소화기연관학회협의회[DOI]
7. Jung HS, "Smoking and the risk of non-alcoholic fatty liver disease: a cohort study", Am J Gastroenterol, 114, pp.453~463 (2019)
8. Kim D, "Body fat distribution and risk of incident and regressed nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 14, pp.132~138.e4 (2016)
9. Kim D, "Effect of longitudinal changes of body fat on the incidence and regression of nonalcoholic fatty liver disease", Dig Liver Dis, 50, pp.389~395 (2018)
10. Kim TJ, "A cohort study on Helicobacter pylori infection associated with nonalcoholic fatty liver disease", J Gastroenterol, 52, pp.1201~1210 (2017)
11. Sinn DH, "Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis", Gastroenterology, 151, pp.481~488.e1 (2016)
12. Kim G, "Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease : a 7-year longitudinal study", Hepatology, 68, pp.1755~1768 (2018)
13. Li J, "Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019 : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 4, pp.389~398 (2019)
14. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-metaanalytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
15. 김형진, "한국 성인에서 비알콜성 지방간의 중증도에 따른 대사이상의 특징", Endocrinology and Metabolism, 17(4), pp.514~525 (2002), 대한내분비학회
16. 정은행, "Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea", Clinical and Molecular Hepatology, 19(3), pp.266~272 (2013), 대한간학회[DOI]
17. Chang Y, "Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population", Am J Gastroenterol, 108, pp.1861~1868 (2013)
18. Lee SB, "Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis : an observational cohort study", J Hepatol, 68, pp.1018~1024 (2018)
19. Jang HR, "Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease : a cohort study", Sci Rep, 8, pp.4718~ (2018)
20. Chang Y, "Alcoholic and nonalcoholic fatty liver disease and liver-related mortality : a cohort study", Am J Gastroenterol, 114, pp.620~629 (2019)
21. Jang EH, "Cardiovascular health metrics in the development and regression of nonalcoholic fatty liver disease : a cohort study", J Clin Med, 8, pp.610~ (2019)
22. Kim JH, "The impact of the sleep duration on NAFLD score in Korean middle-aged adults : a community-based cohort study", Sleep Med, 57, pp.144~150 (2019)
23. Sung KC, "Utility of ALT concentration in men and women with nonalcoholic fatty liver dis ease : cohort study", J Clin Med, 8, pp.445~ (2019)
24. Huh JH, "The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study", PLoS One, 12, pp.e0180951~ (2017)
25. Lee HW, "Prevalence and predictors of significant fibrosis among subjects with transient elastography-defined nonalcoholic fatty liver disease", Dig Dis Sci, 62, pp.2150~2158 (2017)
26. Lee JY, "Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea : a review of 589 consecutive liver biopsies in a single center", J Hepatol, 47, pp.239~244 (2007)
27. Kim HJ, "Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults", Arch Intern Med, 164, pp.2169~2175 (2004)
28. Sung KC, "The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects", Atherosclerosis, 203, pp.581~586 (2009)
29. Chang Wook Chon, "Effect of Nonalcoholic Fatty Liver Disease on the Development of Type 2 Diabetes in Nonobese, Nondiabetic Korean Men", Gut and Liver, 6(3), pp.368~373 (2012), 거트앤리버 소화기연관학회협의회[DOI]
30. Sinn DH, "Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults", Am J Gastroenterol, 107, pp.561~567 (2012)
31. Kim NH, "Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects", Liver Int, 34, pp.604~611 (2014)
32. Hyun Chin Cho, "Prevalence and Factors Associated with Nonalcoholic Fatty Liver Disease in a Nonobese Korean Population", Gut and Liver, 10(1), pp.117~125 (2016), 거트앤리버 소화기연관학회협의회
33. Yang MH, "The associations between apolipoprotein B, A1, and the B", A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population, 2016, pp.10, 289~298
34. Kim SS, "Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects", Dig Liver Dis, 50, pp.370~377 (2018)
35. Wong VW, "Disease progression of non-alcoholic fatty liver disease : a prospective study with paired liver biopsies at 3 years", Gut, 59, pp.969~974 (2010)
36. Pais R, "A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver", J Hepatol, 59, pp.550~556 (2013)
37. McPherson S, "Evidence of NAFLD progression from steatosis to fibrosingsteatohepatitis using paired biopsies : implications for prognosis and clinical management", J Hepatol, 62, pp.1148~1155 (2015)
38. Singh S, "Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis : a systematic review and meta-analysis of pairedbiopsy studies", Clin Gastroenterol Hepatol, 13, pp.643~654 (2015)
39. Matteoni CA, "Nonalcoholic fatty liver disease : a spectrum of clinical and pathological severity", Gastroenterology, 116, pp.1413~1419 (1999)
40. Ahmed A, "Nonalcoholic fatty liver disease review : diagnosis, treatment, and outcomes", Clin Gastroenterol Hepatol, 13, pp.2062~2070 (2015)
41. Wong RJ, "Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States", Gastroenterology, 148, pp.547~555 (2015)
42. Mohamad B, "Characterization of hepatocellular carcinoma(HCC)in non-alcoholic fatty liver disease(NAFLD)patients without cirrhosis", Hepatol Int, 10, pp.632~639 (2016)
43. Younossi ZM, "Association of nonalcoholic fatty liver disease(NAFLD)with hepatocellular carcinoma(HCC)in the United States from 2004 to 2009", Hepatology, 62, pp.1723~1730 (2015)
44. Mittal S, "Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 14, pp.124~131.e1 (2016)
45. Paradis V, "Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis : a pathological analysis", Hepatology, 49, pp.851~859 (2009)
46. Yasui K, "Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma", Clin Gastroenterol Hepatol, 9, pp.428~433 (2011)
47. Paik JM, "Mortality related to nonalcoholic fatty liver disease is increasing in the United States", Hepatol Commun, 3, pp.1459~1471 (2019)
48. Musso G, "Meta-analysis : natural history of non-alcoholic fatty liver disease(NAFLD)and diagnostic accuracy of non-invasive tests for liver disease severity", Ann Med, 43, pp.617~649 (2011)
49. Bril F, "Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD", J Clin Endocrinol Metab, 101, pp.644~652 (2016)
50. Jepsen P, "Prognosis of patients with a diagnosis of fatty liver--a registry-based cohort study", Hepatogastroenterology, 50, pp.2101~2104 (2003)
51. Angulo P, "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease", Gastroenterology, 149, pp.389~397.e10 (2015)
52. Hagström H, "Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD", J Hepatol, 67, pp.1265~1273 (2017)
53. Simon TG, "Mortality in biopsy-confirmed nonalcoholic fatty liver disease : results from a nationwide cohort", Gut, 70, pp.1375~1382 (2021)
54. Younossi ZM, "Non-alcoholic fatty liver disease-a global public health perspective", J Hepatol, 70, pp.531~544 (2019)
55. Udelsman BV, "Risk factors and prevalence of liver disease in review of 2557 routine liver biopsies performed during bariatric surgery", Surg Obes Relat Dis, 15, pp.843~849 (2019)
56. Younossi Z, "Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis", Hepatology, 69, pp.2672~2682 (2019)
57. Non-alcoholic Fatty Liver Disease Study Group, "Epidemiological modifiers of non-alcoholic fatty liver disease : focus on high-risk groups", Dig Liver Dis, 47, pp.997~1006 (2015)
58. Kotronen A, "Liver fat in the metabolic syndrome", J Clin Endocrinol Metab, 92, pp.3490~3497 (2007)
59. Assy N, "Fatty infiltration of liver in hyperlipidemic patients", Dig Dis Sci, 45, pp.1929~1934 (2000)
60. Wu KT, "Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol", J Clin Lipidol, 10, pp.420~425.e1 (2016)
61. Guo Z, "Association of non-alcoholic fatty liver disease with thyroid function : a systematic review and metaanalysis", Dig Liver Dis, 50, pp.1153~1162 (2018)
62. Kumarendran B, "Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women : a longitudinal study based on a United Kingdom primary care database", PLoS Med, 15, pp.e1002542~ (2018)
63. Mesarwi OA, "Obstructive sleep apnea, hypoxia, and nonalcoholic fatty liver disease", Am J Respir Crit Care Med, 199, pp.830~841 (2019)
64. Adams LA, "Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction", Hepatology, 39, pp.909~914 (2004)
65. Mintziori G, "Hypogonadism and non-alcoholic fatty liver disease", Minerva Endocrinol, 42, pp.145~150 (2017)
66. Fujii Y, "Risk factors for development of nonalcoholic fatty liver disease after pancreatoduodenectomy", Ann Gastroenterol Surg, 1, pp.226~231 (2017)
67. Ramos AN, "The linkage between psoriasis and non-alcoholic fatty liver disease : a literature review", Acta Dermatovenerol Croat, 22, pp.132~136 (2014)
68. Hong HC, "Relationship between sarcopenia and nonalcoholic fatty liver disease : the Korean Sarcopenic Obesity Study", Hepatology, 59, pp.1772~1778 (2014)
69. Lee YH, "Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance : nationwide surveys(KNHANES 2008-2011)", J Hepatol, 63, pp.486~493 (2015)
70. Hsieh SD, "Regular physical activity and coronary risk factors in Japanese men", Circulation, 97, pp.661~665 (1998)
71. Perseghin G, "Habitual physical activity is associated with intrahepatic fat content in humans", Diabetes Care, 30, pp.683~688 (2007)
72. Nader PR, "Moderate-to-vigorous physical activity from ages 9 to 15 years", JAMA, 300, pp.295~305 (2008)
73. Goh Eun Chung, "Genetic Polymorphisms of PNPLA3 and SAMM50 Are Associated with Nonalcoholic Fatty Liver Disease in a Korean Population", Gut and Liver, 12(3), pp.316~323 (2018), 거트앤리버 소화기연관학회협의회
74. Eslam M, "A new definition for metabolic dysfunctionassociated fatty liver disease : an international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
75. Lonardo A, "Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?", J Hepatol, 68, pp.335~352 (2018)
76. Andrew A. Li, "Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease", Gut and Liver, 14(2), pp.168~178 (2020), 거트앤리버 소화기연관학회협의회
77. Ballestri S, "Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis", J Gastroenterol Hepatol, 31, pp.936~944 (2016)
78. Ekstedt M, "Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up", Hepatology, 61, pp.1547~1554 (2015)
79. Zeb I, "Nonalcoholic fatty liver disease and incident cardiac events : the multi-ethnic study of atherosclerosis", J Am Coll Cardiol, 67, pp.1965~1966 (2016)
80. Targher G, "Non-alcoholic fatty liver disease and risk of incident cardiovascular disease : a meta-analysis", J Hepatol, 65, pp.589~600 (2016)
81. Sinn DH, "Non-alcoholic fatty liver disease and progression of coronary artery calcium score : a retrospective cohort study", Gut, 66, pp.323~329 (2017)
82. Anstee QM, "Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis", Nat Rev Gastroenterol Hepatol, 10, pp.330~344 (2013)
83. Park J, "NASH", liver fibrosis prevalence and incidence of non-liver comorbidities among people with NAFLD and incidence of NAFLD by metabolic comorbidites: lessons from South Korea, 2021, ~
84. Mantovani A, "nonalcoholic fatty liver disease and risk of incident type 2 diabetes : a meta-analysis", Diabetes Care, 41, pp.372~382 (2018)
85. Ryoo JH, "The clinical availability of non alcoholic fatty liver disease as an early predictor of the metabolic syndrome in Korean men : 5-year’s prospective cohort study", Atherosclerosis, 227, pp.398~403 (2013)
86. Targher G, "CKD and nonalcoholic fatty liver disease", Am J Kidney Dis, 64, pp.638~652 (2014)
87. Targher G, "Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis", Clin J Am Soc Nephrol, 5, pp.2166~2171 (2010)
88. Hwang ST, "Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes", Intern Med J, 40, pp.437~442 (2010)
89. Chang Y, "Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men", Metabolism, 57, pp.569~576 (2008)
90. Musso G, "Association of non-alcoholic fatty liver disease with chronic kidney disease : a systematic review and meta-analysis", PLoS Med, 11, pp.e1001680~ (2014)
91. Sinn DH, "Development of chronic kidney disease in patients with non-alcoholic fatty liver disease : a cohort study", J Hepatol, 67, pp.1274~1280 (2017)
92. Mantovani A, "Cardiovascular disease and myocardial abnormalities in nonalcoholic fatty liver disease", Dig Dis Sci, 61, pp.1246~1267 (2016)
93. Targher G, "Nonalcoholic fatty liver disease and decreased bone mineral density : is there a link?", J Endocrinol Invest, 38, pp.817~825 (2015)
94. Kim GA, "Association between non-alcoholic fatty liver disease and cancer incidence rate", J Hepatol, 68, pp.140~146 (2018)
95. Noureddin M, "Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective : a comprehensive cost-utility analysis", Gastroenterology, 159, pp.1985~1987.e4 (2020)
96. Huang HL, "Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects", Obes Surg, 17, pp.1457~1463 (2007)
97. Rockey DC, "Liver biopsy", Hepatology, 49, pp.1017~1044 (2009)
98. Poynard T, "Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C", Clin Chem, 50, pp.1344~1355 (2004)
99. Ryan CK, "One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation", Liver Transpl, 8, pp.1114~1122 (2002)
100. Wu J, "Prevalence of liver steatosis and fibrosis and the diagnostic accuracy of ultrasound in bariatric surgery patients", Obes Surg, 22, pp.240~247 (2012)
101. Saadeh S, "The utility of radiological imaging in nonalcoholic fatty liver disease", Gastroenterology, 123, pp.745~750 (2002)
102. Kramer H, "Accuracy of liver fat quantification with advanced CT, MRI, and ultrasound techniques : prospective comparison with MR spectroscopy", AJR Am J Roentgenol, 208, pp.92~100 (2017)
103. Myers RP, "Controlled attenuation parameter(CAP) : a non invasive method for the detection of hepatic steatosis based on transient elastography", Liver Int, 32, pp.902~910 (2012)
104. Chan WK, "Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease", J Gastroenterol Hepatol, 29, pp.1470~1476 (2014)
105. Chon YE, "Normal controlled attenuation parameter values : a prospective study of healthy subjects undergoing health checkups and liver donors in Korea", Dig Dis Sci, 60, pp.234~242 (2015)
106. Hong YM, "Clinical usefulness of controlled attenuation parameter to screen hepatic steatosis for potential donor of living donor liver transplant", Eur J Gastroenterol Hepatol, 29, pp.805~810 (2017)
107. Chon YE, "Controlled attenuation parameter(CAP)for detection of hepatic steatosis in patients with chronic liver diseases : a prospective study of a native Korean population", Liver Int, 34, pp.102~109 (2014)
108. Pu K, "Diagnostic accuracy of controlled attenuation parameter(CAP)as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease : a systematic review and meta-analysis", BMC Gastroenterol, 19, pp.51~ (2019)
109. Wong GL, "Transient elastography : kill two birds with one stone?", World J Hepatol, 5, pp.264~274 (2013)
110. Kim TH, "Accuracy of proton magnetic resonance for diagnosing non-alcoholic steatohepatitis : a meta-analysis", Sci Rep, 9, pp.15002~ (2019)
111. Ahn SB, "Optimal cutoff value for assessing changes in intrahepatic fat amount by using the controlled attenuation parameter in a longitudinal setting", Medicine(Baltimore), 97, pp.e13636~ (2018)
112. Ozturk A, "Quantitative hepatic fat quantification in non-alcoholic fatty liver disease using ultrasound-based techniques : a review of literature and their diagnostic performance", Ultrasound Med Biol, 44, pp.2461~2475 (2018)
113. Bae JS, "Assessment of hepatic steatosis by using attenuation imaging : a quantitative, easy-to-perform ultrasound technique", Eur Radiol, 29, pp.6499~6507 (2019)
114. Park SH, "Macrovesicular hepatic steatosis in living liver donors : use of CT for quantitative and qualitative assessment", Radiology, 239, pp.105~112 (2006)
115. Pickhardt PJ, "Specificity of unenhanced CT for non-invasive diagnosis of hepatic steatosis : implications for the investigation of the natural history of incidental steatosis", Eur Radiol, 22, pp.1075~1082 (2012)
116. Fritz GA, "Density histogram analysis of unenhanced hepatic computed tomography in patients with diffuse liver diseases", J Comput Assist Tomogr, 30, pp.201~205 (2006)
117. Limanond P, "Macrovesicular hepatic steatosis in living related liver donors : correlation between CT and histologic findings", Radiology, 230, pp.276~280 (2004)
118. Fishbein M, "Hepatic MRI for fat quantitation : its relationship to fat morphology, diagnosis, and ultrasound", J Clin Gastroenterol, 39, pp.619~625 (2005)
119. Wong VW, "Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease", Am J Gastroenterol, 107, pp.1862~1871 (2012)
120. Idilman IS, "Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy", Radiology, 267, pp.767~775 (2013)
121. Szczepaniak LS, "Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population", Am J Physiol Endocrinol Metab, 288, pp.E462~E468 (2005)
122. Middleton MS, "Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologistassigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis", Gastroenterology, 153, pp.753~761 (2017)
123. Gu J, "Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease : a meta-analysis", Eur Radiol, 29, pp.3564~3573 (2019)
124. Park CC, "Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease", Gastroenterology, 152, pp.598~607.e2 (2017)
125. Boudinaud C, "Quantification of steatosis in alcoholic and nonalcoholic fatty liver disease : evaluation of four MR techniques versus biopsy", Eur J Radiol, 118, pp.169~174 (2019)
126. Bedogni G, "The fatty liver index : a simple and accurate predictor of hepatic steatosis in the general population", BMC Gastroenterol, 6, pp.33~ (2006)
127. Kim JH, "Validation of fatty liver index and lipid accumulation product for predicting fatty liver in Korean population", Liver Int, 31, pp.1600~1601 (2011)
128. Kim JH, "Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke : a large population-based study", Cardiovasc Diabetol, 19, pp.51~ (2020)
129. Kotronen A, "Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors", Gastroenterology, 137, pp.865~872 (2009)
130. Jung JY, "Serum ferritin level is associated with liver steatosis and fibrosis in Korean general population", Hepatol Int, 13, pp.222~233 (2019)
131. Lee JH, "Hepatic steatosis index : a simple screening tool reflecting nonalcoholic fatty liver disease", Dig Liver Dis, 42, pp.503~508 (2010)
132. Chang Jin Won, "Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy", Gut and Liver, 15(1), pp.117~127 (2021), 거트앤리버 소화기연관학회협의회[DOI]
133. Lee HW, "Discrimination of nonalcoholic steatohepatitis using transient elastography in patients with nonalcoholic fatty liver disease", PLoS One, 11, pp.e0157358~ (2016)
134. Cusi K, "Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease", J Hepatol, 60, pp.167~174 (2014)
135. Kwok R, "Systematic review with meta-analysis : non-invasive assessment of nonalcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments", Aliment Pharmacol Ther, 39, pp.254~269 (2014)
136. Thomas EL, "Hepatic triglyceride content and its relation to body adiposity : a magnetic resonance imaging and proton magnetic resonance spectroscopy study", Gut, 54, pp.122~127 (2005)
137. Katsutoshi Sugimoto, "Clinical utilization of shear wave dispersion imaging in diffuse liver disease", ULTRASONOGRAPHY, 39(1), pp.3~10 (2020), 대한초음파의학회
138. Chen J, "Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography", Radiology, 259, pp.749~756 (2011)
139. Allen AM, "The role of three-dimensional magnetic resonance elastography in the diagnosis of nonalcoholic steatohepatitis in obese patients undergoing bariatric surgery", Hepatology, 71, pp.510~521 (2020)
140. Kim JW, "Multiparametric MR index for the diagnosis of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease", Sci Rep, 10, pp.2671~ (2020)
141. Imajo K, "Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography", Gastroenterology, 150, pp.626~637.e7 (2016)
142. Castéra L, "Pitfalls of liver stiffness measurement : a 5-year prospective study of 13, 369 examinations", Hepatology, 51, pp.828~835 (2010)
143. Vuppalanchi R, "Performance characteristics of vibrationcontrolled transient elastography for evaluation of nonalcoholic fatty liver disease", Hepatology, 67, pp.134~144 (2018)
144. Karlas T, "Evaluation of transient elastography, acoustic radiation force impulse imaging(ARFI), and enhanced liver function(ELF)score for detection of fibrosis in morbidly obese patients", PLoS One, 10, pp.e0141649~ (2015)
145. Liu H, "Acoustic radiation force impulse elastography for the non-invasive evaluation of hepatic fibrosis in non-alcoholic fatty liver disease patients : a systematic review &meta-analysis", PLoS One, 10, pp.e0127782~ (2015)
146. Yoneda M, "Nonalcoholic fatty liver disease : US-based acoustic radiation force impulse elastography", Radiology, 256, pp.640~647 (2010)
147. Bota S, "Meta-analysis : ARFI elastography versus transient elastography for the evaluation of liver fibrosis", Liver Int, 33, pp.1138~1147 (2013)
148. Ijin Joo, "Validation of a New Point Shear-Wave Elastography Method for Noninvasive Assessment of Liver Fibrosis: A Prospective Multicenter Study", Korean Journal of Radiology, 20(11), pp.1527~1535 (2019), 대한영상의학회[DOI]
149. Poynard T, "Liver fibrosis evaluation using real-time shear wave elastography : applicability and diagnostic performance using methods without a gold standard", J Hepatol, 58, pp.928~935 (2013)
150. Imajo K, "Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol (2020)[DOI]
151. Loomba R, "Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease : a prospective study", Hepatology, 60, pp.1920~1928 (2014)
152. Kim D, "Advanced fibrosis in nonalcoholic fatty liver disease : noninvasive assessment with MR elastography", Radiology, 268, pp.411~419 (2013)
153. Hsu C, "Mag netic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease : a systematic review and pooled analysis of individual participants", Clin Gastroenterol Hepatol, 17, pp.630~637.e8 (2019)
154. Singh S, "Diagnostic performance of magnetic resonance elastography in staging liver fibrosis : a systematic review and meta-analysis of individual participant data", Clin Gastroenterol Hepatol, 13, pp.440~451.e6 (2015)
155. Singh S, "Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease : a diagnostic accuracy systematic review and individual participant data pooled analysis", Eur Radiol, 26, pp.1431~1440 (2016)
156. Trout AT, "Liver stiffness measurements with MR elastography : agreement and repeatability across imaging systems, field strengths, and pulse sequences", Radiology, 281, pp.793~804 (2016)
157. Shire NJ, "Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C", J Magn Reson Imaging, 34, pp.947~955 (2011)
158. Wang J, "Assessment of advanced hepatic MR elastography methods for susceptibility artifact suppression in clinical patients", J Magn Reson Imaging, 47, pp.976~987 (2018)
159. Srinivasa Babu A, "Elastography in chronic liver disease : modalities, techniques, limitations, and future directions", Radiographics, 36, pp.1987~2006 (2016)
160. Angulo P, "The NAFLD fibrosis score : a noninvasive system that identifies liver fibrosis in patients with NAFLD", Hepatology, 45, pp.846~854 (2007)
161. Qureshi K, "The utility of the"NAFLD fibrosis score"in morbidly obese subjects with NAFLD", Obes Surg, 18, pp.264~270 (2008)
162. Wong VW, "Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis", Am J Gastroenterol, 103, pp.1682~1688 (2008)
163. Guha IN, "Noninvasive markers of fibrosis in nonalcoholic fatty liver disease : validating the european liver fibrosis panel and exploring simple markers", Hepatology, 47, pp.455~460 (2008)
164. Guturu P, "A new risk index for the estimation of fibrosis in non alcoholic fatty liver disease(NAFLD) : comparison with the Mayo Score and the AST platelet ratio index(APRI)", Hepatology, 48, pp.522~ (2008)
165. Harrison SA, "Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease", Gut, 57, pp.1441~1447 (2008)
166. Calès P, "Comparison of blood tests for liver fibrosis specific or not to NAFLD", J Hepatol, 50, pp.165~173 (2009)
167. Ruffillo G, "Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease", J Hepatol, 54, pp.160~163 (2011)
168. Parker R, "Can clinical scoring systems replace liver biopsy in non-alcoholic fatty liver disease?", J Hepatol, 51, pp.189~ (2009)
169. Wong VW, "Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease", Hepatology, 51, pp.454~462 (2010)
170. "EASL Special Conference on NAFLD", NASH and Related Metabolic Disorders 2009, pp.134~ (2009), Elsevier
171. Sumida Y, "A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease", J Gastroenterol, 46, pp.257~268 (2011)
172. Pimentel SK, "Evaluation of the nonalcoholic fat liver disease fibrosis score for patients undergoing bariatric surgery", Arq Gastroenterol, 47, pp.170~173 (2010)
173. Jun DW, "External validation of the non-alcoholic fatty liver disease fibrosis score for assessing advanced fibrosis in Korean patients", J Gastroenterol Hepatol, 32, pp.1094~1099 (2017)
174. Joo SK, "Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease", Liver Int, 38, pp.331~341 (2018)
175. Sterling RK, "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV", HCV coinfection, 2006, pp.43, 1317~1325
176. Tamaki N, "Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease", Sci Rep, 9, pp.10109~ (2019)[DOI]
177. Dong Wook Jekarl, "Diagnosis of Liver Fibrosis With Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFAM2BP) Among Chronic Hepatitis B Patients", Annals of Laboratory Medicine, 38(4), pp.348~354 (2018), 대한진단검사의학회
178. Heo JY, "Use of Wisteria floribunda agglutinin-positive human Mac-2 binding protein in assessing risk of hepatocellular carcinoma due to hepatitis B virus", Medicine (Baltimore), 95, pp.e3328~ (2016)
179. 김승업, "Diagnostic Performance of Serum Asialo-α1-acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease", 대한소화기학회지, 74(6), pp.341~348 (2019), 대한소화기학회[DOI]
180. European Association for the Study of the Liver (EASL), "EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
181. Noureddin M, "Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials", Hepatology, 58, pp.1930~1940 (2013)
182. Caussy C, "Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials", Hepatology, 68, pp.763~772 (2018)
183. Ratziu V, "Sampling variability of liver biopsy in nonalcoholic fatty liver disease", Gastroenterology, 128, pp.1898~1906 (2005)
184. Chalasani N, "The diagnosis and management of non-alcoholic fatty liver disease : practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology", Gastroenterology, 142, pp.1592~1609 (2012)
185. Ratziu V, "A position statement on NAFLD", NASH based on the EASL 2009 special conference, 2010, pp.53, 372~384
186. Boursier J, "Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in nonalcoholic fatty liver disease", J Hepatol, 65, pp.570~578 (2016)
187. Tapper EB, "Costeffective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography", Am J Gastroenterol, 110, pp.1298~1304 (2015)
188. Gunn NT, "The use of liver biopsy in nonalcoholic fatty liver disease : when to biopsy and in whom", Clin Liver Dis, 22, pp.109~119 (2018)
189. Janiec DJ, "Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies", Obes Surg, 15, pp.497~501 (2005)
190. Merriman RB, "Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease", Hepatology, 44, pp.874~880 (2006)
191. Younossi ZM, "Nonalcoholic fatty liver disease : assessment of variability in pathologic interpretations", Mod Pathol, 11, pp.560~565 (1998)
192. Sanyal AJ, "Endpoints and clinical trial design for nonalcoholic steatohepatitis", Hepatology, 54, pp.344~353 (2011)
193. Brunt EM, "Nonalcoholic steatohepatitis : a proposal for grading and staging the histological lesions", Am J Gastroenterol, 94, pp.2467~2474 (1999)
194. Bedossa P, "Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients", Hepatology, 56, pp.1751~1759 (2012)
195. Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
196. Ascha MS, "The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis", Hepatology, 51, pp.1972~1978 (2010)
197. Yatsuji S, "Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C", J Gastroenterol Hepatol, 24, pp.248~254 (2009)
198. Loomba R, "AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease : expert review", Gastroenterology, 158, pp.1822~1830 (2020)
199. Castera L, "Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease", Gastroenterology, 156, pp.1264~1281.e4 (2019)
200. Tapper EB, "Use of liver imaging and biopsy in clinical practice", N Engl J Med, 377, pp.2296~2297 (2017)
201. Tapper EB, "Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD", Nat Rev Gastroenterol Hepatol, 15, pp.274~282 (2018)
202. Reig M, "Should patients with NAFLD", NASH be surveyed for HCC?, 2019, pp.103, 39~44
203. White DL, "Association between nonalco holic fatty liver disease and risk for hepatocellular cancer, based on systematic review", Clin Gastroenterol Hepatol, 10, pp.1342~1359.e2 (2012)
204. Kanwal F, "Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease", Gastroenterology, 155, pp.1828~1837.e2 (2018)
205. Del Poggio P, "Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis", Clin Gastroenterol Hepatol, 12, pp.1927~1933.e2 (2014)
206. Simmons O, "Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis", Aliment Pharmacol Ther, 45, pp.169~177 (2017)
207. Lee YC, "Metaanalysis of epidemiologic studies on cigarette smoking and liver cancer", Int J Epidemiol, 38, pp.1497~1511 (2009)
208. Petrick JL, "Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma : the liver cancer pooling project", Br J Cancer, 118, pp.1005~1012 (2018)
209. Turati F, "Alcohol and liver cancer : a systematic review and meta-analysis of prospective studies", Ann Oncol, 25, pp.1526~1535 (2014)
210. Bagnardi V, "Alcohol consumption and site-specific cancer risk : a comprehensive dose-response meta-analysis", Br J Cancer, 112, pp.580~593 (2015)
211. Simon TG, "Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma : results from two prospective cohort studies", Hepatology, 67, pp.1797~1806 (2018)
212. El-Serag HB, "The association between diabetes and hepatocellular carcinoma : a systematic review of epidemiologic evidence", Clin Gastroenterol Hepatol, 4, pp.369~380 (2006)
213. Wang C, "Increased risk of hepatocellular carcinoma in patients with diabetes mellitus : a systematic review and meta-analysis of cohort studies", Int J Cancer, 130, pp.1639~1648 (2012)
214. Yang WS, "The role of preexisting diabetes mellitus on hepatocellular carcinoma occurrence and prognosis : a meta-analysis of prospective cohort studies", PLoS One, 6, pp.e27326~ (2011)
215. Stefan N, "Non-alcoholic fatty liver disease : causes, diagnosis, cardiometabolic consequences, and treatment strategies", Lancet Diabetes Endocrinol, 7, pp.313~324 (2019)
216. Singh S, "Anti-diabetic medications and the risk of hepatocellular cancer : a systematic review and meta-analysis", Am J Gastroenterol, 108, pp.881~891 (2013)
217. Cusi K, "Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus : a randomized trial", Ann Intern Med, 165, pp.305~315 (2016)
218. Armstrong MJ, "Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis(LEAN) : a multicentre, double-blind, randomised, placebo-controlled phase 2 study", Lancet, 387, pp.679~690 (2016)
219. Younossi ZM, "Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis", Hepatology, 68, pp.361~371 (2018)
220. Singh S, "Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis : a systematic review and network meta-analysis", Hepatology, 62, pp.1417~1432 (2015)
221. Singh S, "Statins are associated with a reduced risk of hepatocellular cancer : a systematic review and meta-analysis", Gastroenterology, 144, pp.323~332 (2013)
222. Friis S, "Cancer risk among statin users : a population-based cohort study", Int J Cancer, 114, pp.643~647 (2005)
223. El-Serag HB, "Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes", Gastroenterology, 136, pp.1601~1608 (2009)
224. Wong CR, "Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease", World J Gastroenterol, 22, pp.8294~8303 (2016)
225. Ekstedt M, "Long-term follow-up of patients with NAFLD and elevated liver enzymes", Hepatology, 44, pp.865~873 (2006)
226. Adams LA, "The natural history of nonalcoholic fatty liver disease : a population-based cohort study", Gastroenterology, 129, pp.113~121 (2005)
227. Dulai PS, "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease : systematic review and meta-analysis", Hepatology, 65, pp.1557~1565 (2017)
228. Taylor RS, "Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease : a systematic review and meta-analysis", Gastroenterology, 158, pp.1611~1625.e12 (2020)
229. Kleiner DE, "Association of histologic disease activity with progression of nonalcoholic fatty liver disease", JAMA Netw Open, 2, pp.e1912565~ (2019)
230. Brunt EM, "Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis clinical research network treatment trials", Hepatology, 70, pp.522~531 (2019)
231. Lazo M, "Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes", Diabetes Care, 33, pp.2156~2163 (2010)
232. Kirk E, "Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction", Gastroenterology, 136, pp.1552~1560 (2009)
233. Promrat K, "Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis", Hepatology, 51, pp.121~129 (2010)
234. Vilar-Gomez E, "Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis", Gastroenterology, 149, pp.367~378.e5 (2015)
235. Jin YJ, "Exercise and diet modification in non-obese non-alcoholic fatty liver disease : analysis of biopsies of living liver donors", J Gastroenterol Hepatol, 27, pp.1341~1347 (2012)
236. Koutoukidis DA, "Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease : a systematic review and meta-analysis", JAMA Intern Med, 179, pp.1262~1271 (2019)
237. Wong VW, "Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease", J Hepatol, 69, pp.1349~1356 (2018)
238. Huang MA, "One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis : a pilot study", Am J Gastroenterol, 100, pp.1072~1081 (2005)
239. Andersen T, "Hepatic effects of dietary weight loss in morbidly obese subjects", J Hepatol, 12, pp.224~229 (1991)
240. Tsai JH, "Aggressive non-alcoholic steatohepatitis following rapid weight loss and", or malnutrition, 2017, pp.30, 834~842
241. Haufe S, "Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects", Hepatology, 53, pp.1504~1514 (2011)
242. Browning JD, "Short-term weight loss and hepatic triglyceride reduction : evidence of a metabolic advantage with dietary carbohydrate restriction", Am J Clin Nutr, 93, pp.1048~1052 (2011)
243. 서미혜, "2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea", Journal of Obesity & Metabolic Syndrome, 28(1), pp.40~45 (2019), 대한비만학회[DOI]
244. Kang H, "Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD", Am J Gastroenterol, 101, pp.2247~2253 (2006)
245. Toshimitsu K, "Dietary habits and nutrient intake in non-alcoholic steatohepatitis", Nutrition, 23, pp.46~52 (2007)
246. Jun DW, "Influence of dietary intake on non-alcoholic fatty liver disease in Korean" (2012), National Institute of Food and Drug Safety Evaluation
247. Jang EC, "Comparison of efficacy of low-carbohydrate and low-fat diet education programs in nonalcoholic fatty liver disease : a randomized controlled study", Hepatol Res, 48, pp.E22~E29 (2018)
248. Ahn J, "Critical appraisal for low-carbohydrate diet in nonalcoholic fatty liver disease : review and metaanalyses", Clin Nutr, 38, pp.2023~2030 (2019)
249. Castro-Quezada I, "The Mediterranean diet and nutritional adequacy : a review", Nutrients, 6, pp.231~248 (2014)
250. Gepner Y, "The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content", J Hepatol, 71, pp.379~388 (2019)
251. Properzi C, "Ad libitum mediterranean and low-fat diets both significantly reduce hepatic steatosis : a randomized controlled trial", Hepatology, 68, pp.1741~1754 (2018)
252. Theresa J. Hydes, "Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH", Clinical and Molecular Hepatology, 26(4), pp.383~400 (2020), 대한간학회[DOI]
253. Scorletti E, "Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes : results from the WELCOME trial", J Hepatol, 63, pp.1476~1483 (2015)
254. Ryu S, "Relationship of sitting time and physical activity with non-alcoholic fatty liver disease", J Hepatol, 63, pp.1229~1237 (2015)
255. Sung KC, "Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver", J Hepatol, 65, pp.791~797 (2016)
256. Kistler KD, "Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease", Am J Gastroenterol, 106, pp.460~468 (2011)
257. Hallsworth K, "Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss", Gut, 60, pp.1278~1283 (2011)
258. Sullivan S, "Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease", Hepatology, 55, pp.1738~1745 (2012)
259. Cassidy S, "High intensity intermittent exercise improves cardiac structure and function and reduces liver fat in patients with type 2diabetes : a randomised controlled trial", Diabetologia, 59, pp.56~66 (2016)
260. Johnson NA, "Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss", Hepatology, 50, pp.1105~1112 (2009)
261. Keating SE, "Effect of aerobic exercise training dose on liver fat and visceral adiposity", J Hepatol, 63, pp.174~182 (2015)
262. Houghton D, "Exercise reduces liver lipids and visceral adiposity in patients with nonalcoholic steatohepatitis in a randomized controlled trial", Clin Gastroenterol Hepatol, 15, pp.96~102.e3 (2017)
263. Keating SE, "Exercise and nonalcoholic fatty liver disease : a systematic review and meta-analysis", J Hepatol, 57, pp.157~166 (2012)
264. Thoma C, "Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults : a systematic review", J Hepatol, 56, pp.255~266 (2012)
265. Kenneally S, "Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease : a systematic review", BMJ Open Gastroenterol, 4, pp.e000139~ (2017)
266. Shamsoddini A, "Effect of aerobic and resistance exercise training on liver enzymes and hepatic fat in Iranian men with nonalcoholic fatty liver disease", Hepat Mon, 15, pp.e31434~ (2015)
267. Bacchi E, "Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease(the RAED2 Randomized Trial)", Hepatology, 58, pp.1287~1295 (2013)
268. "What is moderate-intensity and vigorous-intensity physical activity"[URL]
269. Piercy KL, "The physical activity guidelines for Americans", JAMA, 320, pp.2020~2028 (2018)
270. Slentz CA, "Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT", RT, 2011, pp.301, E1033~E1039
271. Hashida R, "Aerobic vs. resistance exercise in non-alcoholic fatty liver disease : a systematic review", J Hepatol, 66, pp.142~152 (2017)
272. Katsagoni CN, "Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease : a meta-analysis", Metabolism, 68, pp.119~132 (2017)
273. Pugh CJ, "Exercise-induced improvements in liver fat and endothelial function are not sustained 12 months following cessation of exercise supervision in nonalcoholic fatty liver disease", Int J Obes(Lond), 40, pp.1927~1930 (2016)
274. Dunn W, "Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with nonalcoholic fatty liver disease(NAFLD)", J Hepatol, 57, pp.384~391 (2012)
275. Dunn W, "Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease", Hepatology, 47, pp.1947~1954 (2008)
276. Moriya A, "Roles of alcohol consumption in fatty liver : a longitudinal study", J Hepatol, 62, pp.921~927 (2015)
277. Kwon HK, "Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease", Liver Int, 34, pp.129~135 (2014)
278. Dixon JB, "Nonalcoholic fatty liver disease : predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese", Gastroenterology, 121, pp.91~100 (2001)
279. Mitchell T, "Type and pattern of alcohol consumption is associated with liver fibrosis in patients with non-alcoholic fatty liver disease", Am J Gastroenterol, 113, pp.1484~1493 (2018)
280. Hart CL, "Effect of body mass index and alcohol consumption on liver disease:analysis of data from two prospective cohort studies", BMJ, 340, pp.c124~ (2010)
281. Ekstedt M, "Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease", Scand J Gastroenterol, 44, pp.366~374 (2009)
282. Lau K, "The combined effects of alcohol consumption and body mass index on hepatic steatosis in a general population sample of European men and women", Aliment Pharmacol Ther, 41, pp.467~476 (2015)
283. Chang Y, "Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease : a cohort study", Hepatology, 69, pp.64~75 (2019)
284. NIH conference, "Gastrointestinal surgery for severe obesity. Consensus development conference panel", Ann Intern Med, 115, pp.956~961 (1991)
285. Marra F, "Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells", Gastroenterology, 119, pp.466~478 (2000)
286. Galli A, "Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro", Gastroenterology, 122, pp.1924~1940 (2002)
287. Bril F, "Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes", Clin Gastroenterol Hepatol, 16, pp.558~566.e2 (2018)
288. Kalavalapalli S, "Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis", Am J Physiol Endocrinol Metab, 315, pp.E163~E173 (2018)
289. Belfort R, "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis", N Engl J Med, 355, pp.2297~2307 (2006)
290. Aithal GP, "Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis", Gastroenterology, 135, pp.1176~1184 (2008)
291. Sanyal AJ, "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis", N Engl J Med, 362, pp.1675~1685 (2010)
292. Ratziu V, "Rosiglitazone for nonalcoholic steatohepatitis : one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy(FLIRT)trial", Gastroenterology, 135, pp.100~110 (2008)
293. Ratziu V, "Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis : results of the fatty liver improvement by rosiglitazone therapy(FLIRT 2)extension trial", Hepatology, 51, pp.445~453 (2010)
294. Mahady SE, "The role of thiazolidinediones in non-alcoholic steatohepatitis-a systematic review and meta analysis", J Hepatol, 55, pp.1383~1390 (2011)
295. Kahn SE, "Rosiglitazone-associated fractures in type 2 diabetes : an analysis from a diabetes outcome progression trial(ADOPT)", Diabetes Care, 31, pp.845~851 (2008)
296. Lewis JD, "Risk of bladder cancer among diabetic patients treated with pioglitazone : interim report of a longitudinal cohort study", Diabetes Care, 34, pp.916~922 (2011)
297. Lincoff AM, "Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus : a meta-analysis of randomized trials", JAMA, 298, pp.1180~1188 (2007)
298. Lin HZ, "Metformin reverses fatty liver disease in obese, leptin-deficient mice", Nat Med, 6, pp.998~1003 (2000)
299. Zhou G, "Role of AMP-activated protein kinase in mechanism of metformin action", J Clin Invest, 108, pp.1167~1174 (2001)
300. Bugianesi E, "A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease", Am J Gastroenterol, 100, pp.1082~1090 (2005)
301. Uygun A, "Metformin in the treatment of patients with non-alcoholic steatohepatitis", Aliment Pharmacol Ther, 19, pp.537~544 (2004)
302. Haukeland JW, "Metformin in patients with nonalcoholic fatty liver disease : a randomized, controlled trial", Scand J Gastroenterol, 44, pp.853~860 (2009)
303. Duseja A, "Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease(NAFLD)not responding to lifestyle interventions", Ann Hepatol, 6, pp.222~226 (2007)
304. Idilman R, "Clinical trial : insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis", Aliment Pharmacol Ther, 28, pp.200~208 (2008)
305. Nar A, "The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease", Acta Diabetol, 46, pp.113~118 (2009)
306. Omer Z, "Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease", Eur J Gastroenterol Hepatol, 22, pp.18~23 (2010)
307. Musso G, "Impact of current treatments on liver disease, glucose metabolism and cardiovascu lar risk in non-alcoholic fatty liver disease(NAFLD) : a systematic review and meta-analysis of randomised trials", Diabetologia, 55, pp.885~904 (2012)
308. Vilar-Gomez E, "Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis", Aliment Pharmacol Ther, 50, pp.317~328 (2019)
309. Kaplan DE, "Effects of metformin exposure on survival in a large national cohort of patients with diabetes and cirrhosis", Clin Gastroenterol Hepatol (2020)[DOI]
310. Newsome PN, "A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis", N Engl J Med, 384, pp.1113~1124 (2021)
311. Hasegawa T, "Plasma transforming growth factor-beta1 level and efficacy of alphatocopherol in patients with non-alcoholic steatohepatitis : a pilot study", Aliment Pharmacol Ther, 15, pp.1667~1672 (2001)
312. Harrison SA, "Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis", Am J Gastroenterol, 98, pp.2485~2490 (2003)
313. Klein EA, "Vitamin E and the risk of prostate cancer : the selenium and vitamin E cancer prevention trial(SELECT)", JAMA, 306, pp.1549~1556 (2011)
314. Miller ER 3rd, "Meta-analysis : high-dosage vitamin E supplementation may increase all-cause mortality", Ann Intern Med, 142, pp.37~46 (2005)
315. Curtis AJ, "Vitamin E supplementation and mortality in healthy people : a meta-analysis of randomised controlled trials", Cardiovasc Drugs Ther, 28, pp.563~573 (2014)
316. Aune D, "Dietary intake and blood concentrations of antioxidants and the risk of cardiovascular disease, total cancer, and all-cause mortality : a systematic review and dose-response meta-analysis of prospective studies", Am J Clin Nutr, 108, pp.1069~1091 (2018)
317. Vilar-Gomez E, "Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis", Hepatology, 71, pp.495~509 (2020)
318. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
319. Tabenkin H, "Differences in cardiovascular disease risk factor management in primary care by sex of physician and patient", Ann Fam Med, 8, pp.25~32 (2010)
320. Byrne CD, "NAFLD : a multisystem disease", J Hepatol, 62(1 Suppl), pp.S47~S64 (2015)
321. Fracanzani AL, "Carotid artery intima-media thickness in nonalcoholic fatty liver disease", Am J Med, 121, pp.72~78 (2008)
322. National cholesterol education program, "Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults(Adult Treatment Panel II)", Circulation, 89, pp.1333~1445 (1994)
323. Pastori D, "The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease", Dig Liver Dis, 47, pp.4~11 (2015)
324. Arnett DK, "2019 ACC", AHA guideline on the primary prevention of cardiovascular disease : a report of the American College of Cardiology, J Am Coll Cardiol, pp.2019, 74[DOI]
325. Athyros VG, "Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation(GREACE)study : a post-hoc analysis", Lancet, 376, pp.1916~1922 (2010)
326. Lee JI, "Effects of statin use on the development and progression of nonalcoholic fatty liver disease : a nationwide nested case-control study", Am J Gastroenterol, 116, pp.116~124 (2020)
327. Khoo S, "Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease", J Gastroenterol Hepatol, 35, pp.320~325 (2020)
328. Chalasani N, "Statins and hepatotoxicity : focus on patients with fatty liver", Hepatology, 41, pp.690~695 (2005)
329. Dale KM, "Impact of statin dosing intensity on transaminase and creatine kinase", Am J Med, 120, pp.706~712 (2007)
330. Law M, "Statin safety : a systematic review", Am J Cardiol, 97(8A), pp.52C~60C (2006)
331. Chalasani N, "Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity", Gastroenterology, 126, pp.1287~1292 (2004)
332. Lewis JH, "Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease : results of a prospective, randomized, double-blind, placebocontrolled, multicenter trial", Hepatology, 46, pp.1453~1463 (2007)
333. Bays H, "An assessment by the Statin Liver Safety Task Force : 2014 update", J Clin Lipidol, 8(3Suppl), pp.S47~S57 (2014)
334. Cohen DE, "An assessment of statin safety by hepatologists", Am J Cardiol, 97(8A), pp.77C~81C (2006)
335. Kumar S, "Statin use in patients with cirrhosis : a retrospective cohort study", Dig Dis Sci, 59, pp.1958~1965 (2014)
336. Stone NJ, "2013 ACC", AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults : a report of the American College of Cardiology, Circulation, pp.2014, 129(25 Suppl 2)[DOI]
337. Watanabe S, "Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease", nonalcoholic steatohepatitis, 2015, pp.50, 364~377
338. Simon TG, "The nonalcoholic fatty liver disease(NAFLD)fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe", Int J Cardiol, 270, pp.245~252 (2018)
339. Parker HM, "Omega-3 supplementation and non-alcoholic fatty liver disease : a systematic review and meta-analysis", J Hepatol, 56, pp.944~951 (2012)
340. Sanyal AJ, "No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial", Gastroenterology, 147, pp.377~384.e1 (2014)
341. Argo CK, "Effects of n-3 fish oil on metabolic and histological parameters in NASH : a double-blind, randomized, placebo-controlled trial", J Hepatol, 62, pp.190~197 (2015)
342. Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
343. Scorletti E, "Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease : results from the Welcome*study", Hepatology, 60, pp.1211~1221 (2014)
344. Harrison SA, "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH : results from randomized phase III STELLAR trials", J Hepatol, 73, pp.26~39 (2020)
345. Younossi ZM, "Obeticholic acid for the treatment of non-alcoholic steatohepatitis : interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial", Lancet, 394, pp.2184~2196 (2019)
346. Miller CM, "The international liver transplantation society living donor liver transplant recipient guideline", Transplantation, 101, pp.938~944 (2017)
347. Pillai AA, "Non-alcoholic fatty liver disease : is bariatric surgery the answer?", Clin Liver Dis, 13, pp.689~710 (2009)
348. Lee Y, "Complete resolution of nonalcoholic fatty liver disease after bariatric surgery : a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 17, pp.1040~1060.e11 (2019)
349. Mathurin P, "Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease", Gastroenterology, 137, pp.532~540 (2009)
350. Mummadi RR, "Effect of bariatric surgery on nonalcoholic fatty liver disease : systematic review and meta-analysis", Clin Gastroenterol Hepatol, 6, pp.1396~1402 (2008)
351. Chavez-Tapia NC, "Bariatric surgery for nonalcoholic steatohepatitis in obese patients", Cochrane Database Syst Rev, 2010, pp.CD007340~ (2010)
352. Lassailly G, "Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis", Gastroenterology, 159, pp.1290~1301.e5 (2020)
353. Fakhry TK, "Bariatric surgery improves nonalcoholic fatty liver disease : a contemporary systematic review and meta-analysis", Surg Obes Relat Dis, 15, pp.502~511 (2019)
354. Bower G, "Bariatric surgery and non-alcoholic fatty liver disease : a systematic review of liver biochemistry and histology", Obes Surg, 25, pp.2280~2289 (2015)
355. Brolin RE, "Unsuspected cirrhosis discovered during elective obesity operations", Arch Surg, 133, pp.84~88 (1998)
356. Dallal RM, "Results of laparoscopic gastric bypass in patients with cirrhosis", Obes Surg, 14, pp.47~53 (2004)
357. Shimizu H, "Bariatric surgery in patients with liver cirrhosis", Surg Obes Relat Dis, 9, pp.1~6 (2013)
358. Jan A, "A systematic review of bariatric surgery in patients with liver cirrhosis", Obes Surg, 25, pp.1518~1526 (2015)
359. Car Peterko A, "Diagnosis and management of acute and early complications of", after bariatric surgery, 2012, pp.30, 178~181
360. Hammer HF, "Medical complications of bariatric surgery : focus on malabsorption and dumping syndrome", Dig Dis, 30, pp.182~186 (2012)
361. Decker GA, "Gastrointestinal and nutritional complications after bariatric surgery", Am J Gastroenterol, 102, pp.2571~2580 (2007)
362. Charlton MR, "Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States", Gastroenterology, 141, pp.1249~1253 (2011)
363. Tsochatzis E, "International liver transplantation consensus statement on endstage liver disease due to nonalcoholic steatohepatitis and liver transplantation", Transplantation, 103, pp.45~56 (2019)
364. Wang X, "Outcomes of liver transplantation for nonalcoholic steatohepatitis : a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 12, pp.394~402.e1 (2014)
365. Heuer M, "Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications : a single-center experience", Digestion, 86, pp.107~113 (2012)
366. Everhart JE, "Weight change and obesity after liver transplantation : incidence and risk factors", Liver Transpl Surg, 4, pp.285~296 (1998)
367. Patil DT, "Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation", Liver Transpl, 18, pp.1147~1153 (2012)
368. Laish I, "Metabolic syndrome in liver transplant recipients : prevalence, risk factors, and association with cardiovascular events", Liver Transpl, 17, pp.15~22 (2011)
369. Park SH, "The change in prevalence of suspected non-alcoholic fatty liver disease in Korean adolescents from 2001 to 2017", Paediatr Int Child Health, 40, pp.166~170 (2020)
370. 강윤구, "Estimated Prevalence of Adolescents with Nonalcoholic Fatty Liver Disease in Korea", Journal of Korean Medical Science, 33(14), pp.29~38 (2018), 대한의학회
371. 문진수, "2007 한국 소아 청소년 성장도표 : 개발 과정과 전망", Clinical and Experimental Pediatrics, 51(1), pp.1~25 (2008), 대한소아청소년과학회
372. "Korea National Health and Nutrition Examination Survey: Analytic guidelines"[URL]
373. Roberts EA, "Pediatric nonalcoholic fatty liver disease(NAFLD) : a"growing"problem?", J Hepatol, 46, pp.1133~1142 (2007)
374. Feldstein AE, "The natural history of non-alcoholic fatty liver disease in children : a follow-up study for up to 20 years", Gut, 58, pp.1538~1544 (2009)
375. Nobili V, "Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy : coincidence or comorbidity", Pediatr Obes, 9, pp.e99~e102 (2014)
376. Doycheva I, "Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in young adults in the United States", J Clin Gastroenterol, 52, pp.339~346 (2018)
377. Alkhouri N, "Liver transplantation for nonalcoholic steatohepatitis in young patients", Transpl Int, 29, pp.418~424 (2016)
378. Loomba R, "Advances in pediatric nonalcoholic fatty liver disease", Hepatology, 50, pp.1282~1293 (2009)
379. Papandreou D, "Update on non-alcoholic fatty liver disease in children", Clin Nutr, 26, pp.409~415 (2007)
380. Schwimmer JB, "Heritability of nonalcoholic fatty liver disease", Gastroenterology, 136, pp.1585~1592 (2009)
381. Eslam M, "Genetics and epigenetics of NAFLD and NASH : clinical impact", J Hepatol, 68, pp.268~279 (2018)
382. Caussy C, "Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis", J Clin Invest, 127, pp.2697~2704 (2017)
383. Goyal NP, "The genetics of pediatric nonalcoholic fatty liver disease", Clin Liver Dis, 22, pp.59~71 (2018)
384. Di Sessa A, "The membrane-bound O-acyltransferase7 rs641738variant in pediatric nonalcoholic fatty liver disease", J Pediatr Gastroenterol Nutr, 67, pp.69~74 (2018)
385. Hudert CA, "Genetic determinants of steatosis and fibrosis progression in paediatric non-alcoholic fatty liver disease", Liver Int, 39, pp.540~556 (2019)
386. Krawczyk M, "Combined effects of the PNPLA3 rs738409, TM6SF2rs58542926, and MBOAT7 rs641738 variants on NAFLD severity : a multicenter biopsy-based study", J Lipid Res, 58, pp.247~255 (2017)
387. Lin YC, "A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children", J Pediatr, 158, pp.740~744 (2011)
388. Jain V, "Genetic polymorphisms associated with obesity and non-alcoholic fatty liver disease in Asian Indian adolescents", J Pediatr Endocrinol Metab, 32, pp.749~758 (2019)
389. Lombardi R, "Combined use of genetic polymorphisms and elastographic techniques in NAFLD : fact or fiction?", Curr Pharm Des, 26, pp.1010~1018 (2020)
390. Stanislawski MA, "Genetic risk for hepatic fat among an ethnically diverse cohort of youth : the exploring perinatal outcomes among children study", J Pediatr, 220, pp.146~153.e2 (2020)
391. Youssefian L, "Inherited non-alcoholic fatty liver disease and dyslipidemia due to monoallelic ABHD5 mutations", J Hepatol, 71, pp.366~370 (2019)
392. Lee EY, "Health behavior associated with liver enzymes among obese Korean adolescents, 2009-2014", PLoS One, 13, pp.e0190535~ (2018)
393. Barlow SE, "Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report", Pediatrics, 120(Suppl 4), pp.S164~S192 (2007)
394. Di Bonito P, "Association of elevated serum alanine aminotransferase with metabolic factors in obese children : sex-related analysis", Metabolism, 58, pp.368~372 (2009)
395. Yoo J, "Relationship between insulin resistance and serum alanine aminotransferase as a surrogate of NAFLD(nonalcoholic fatty liver disease)in obese Korean children", Diabetes Res Clin Pract, 81, pp.321~326 (2008)
396. Vajro P, "Diagnosis of nonalcoholic fatty liver disease in children and adolescents : position paper of the ESPGHAN Hepatology Committee", J Pediatr Gastroenterol Nutr, 54, pp.700~713 (2012)
397. Dae Yong Yi, "Clinical practice guideline for the diagnosis and treatment of pediatric obesity: recommendations from the Committee on Pediatric Obesity of the Korean Society of Pediatric Gastroenterology Hepatology and Nutrition", Clinical and Experimental Pediatrics, 62(1), pp.3~21 (2019), 대한소아청소년과학회
398. Vos MB, "NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children : recommendations from the Expert Committee on NAFLD(ECON)and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition(NASPGHAN)", J Pediatr Gastroenterol Nutr, 64, pp.319~334 (2017)
399. "The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the American Association for the Study of Liver Diseases", Clin Liver Dis(Hoboken), 11, pp.81~ (2018)
400. Vuppalanchi R, "Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 12, pp.2121~2130.e1-e2 (2014)
401. Ebbeling CB, "A randomized trial of sugar-sweetened beverages and adolescent body weight", N Engl J Med, 367, pp.1407~1416 (2012)
402. Brown T, "Interventions for preventing obesity in children", Cochrane Database Syst Rev, 7, pp.CD001871~ (2019)
403. de Ruyter JC, "A trial of sugar-free or sugar-sweetened beverages and body weight in children", N Engl J Med, 367, pp.1397~1406 (2012)
404. Bjelakovic G, "Antioxidant supplements and mortality", Curr Opin Clin Nutr Metab Care, 17, pp.40~44 (2014)
405. Bjelakovic G, "Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases", Cochrane Database Syst Rev, (3), pp.CD007176~ (2012)
406. Gerss J, "The questionable association of vitamin E supplementation and mortality--inconsistent results of different meta-analytic approaches", Cell Mol Biol (Noisy-le-grand), 55, pp.OL1111~OL1120 (2009)
407. Lavine JE, "Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents : the TONIC randomized controlled trial", JAMA, 305, pp.1659~1668 (2011)
408. Lindor KD, "Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis : results of a randomized trial", Hepatology, 39, pp.770~778 (2004)
409. Nobili V, "Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease : double-blind randomised controlled clinical trial", Arch Dis Child, 96, pp.350~353 (2011)
410. Barker KB, "Non-alcoholic steatohepatitis : effect of Roux-en-Y gastric bypass surgery", Am J Gastroenterol, 101, pp.368~373 (2006)
411. O’Brien PE, "Laparoscopic adjustable gastric banding in severely obese adolescents : a randomized trial", JAMA, 303, pp.519~526 (2010)
412. Jensen MD, "2013 AHA", ACC, American Heart Association Task Force on practice guidelines and The Obesity Society, pp.Circulation, 2014[DOI]
413. Gordon SC, "Health care use and costs among patients with nonalcoholic steatohepatitis with advanced fibrosis using the fibrosis-4 score", Hepatol Commun, 4, pp.998~1011 (2020)
414. Vali Y, "Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD : a systematic review and meta-analysis", J Hepatol, 73, pp.252~262 (2020)

관련 논문AI추천